Soleno Therapeutics Inc

Insider sales reveal Soleno Therapeutics’ CEO liquidating 37,639 shares at merger‑price amid a Nasdaq trading halt—insight into liquidity strategy and merger timing for investors.

Insider sales at Soleno Therapeutics reveal tax‑planning moves, not a warning sign. Understand the impact of leadership trades on the company’s future.

Insider buying by Soleno Therapeutics’ CFO signals confidence amid stock decline – learn how executive stakes could drive future value.